相关临床试验
176
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1495
进行中（未招募）
5
2.8%
已完成
131
74.4%
Enrolling By Invitation
3
1.7%
尚未招募
4
2.3%
招募中
17
9.7%
暂停
1
0.6%
终止
4
2.3%
Unknown
9
5.1%
撤回
2
1.1%
暂无批准数据
- The Sustainable Aquaculture Innovation Cluster (SAIC) has appointed 14 international experts to a new science panel to guide its research and innovation funding decisions. - The panel, chaired by Pieter van West of the University of Aberdeen, spans fish and shellfish health, environmental science, veterinary medicine, seaweed, and technology. - The appointments coincide with SAIC's first full funding call since becoming independent from the University of Stirling, launched on 24 August. - SAIC secured £1.4 million in annual funding for at least five years from Crown Estate Scotland, supporting its relocation to the Highlands.
- A 25-year study of 22,534 UK adults found men with cardiovascular disease had a 17.3% lifetime cancer risk, compared with 12.8% for women with CVD. - Smoking, obesity and excessive alcohol consumption were identified as the primary drivers, with the strongest links seen in lung and oesophageal cancers. - Men with CVD also faced elevated mortality from gastric, oesophageal and lung cancers, prompting calls for improved risk management and targeted screening. - Researchers urged new care pathways to identify and prevent cancer in patients with cardiac conditions, reversing the current cardio-oncology focus.
- Aberdeen Royal Infirmary has been designated as the regional CAR-T treatment center for northern Scotland, eliminating the need for patients to travel hundreds of miles to Newcastle for this life-saving therapy. - Nancy Gray, 68, became the first patient to receive CAR-T therapy at the facility in November 2024 and achieved remission by July, demonstrating the treatment's effectiveness for relapsed lymphoma. - The revolutionary cellular immunotherapy reprograms patients' own T-cells to recognize and destroy cancer cells, offering hope for blood cancer patients who haven't responded to conventional treatments like chemotherapy. - Consultant haematologist Gavin Preston described CAR-T as "a massive breakthrough" that establishes Aberdeen Royal Infirmary as a center of excellence in haematology care.
- Researchers at University College London have successfully treated Huntington's disease for the first time using gene therapy AMT-130, achieving a 75% reduction in disease progression after three years. - The breakthrough represents the first statistically significant slowing of Huntington's disease progression in clinical trials, offering hope for patients with this devastating hereditary neurological condition. - The gene therapy is delivered through a single 12-20 hour surgical procedure that inactivates the toxic huntingtin protein responsible for the disease's brain cell destruction. - The results are particularly significant for northern Scotland, which has one of the world's highest rates of Huntington's disease at 14.5 per 100,000 people.
- An international research team led by CAMH has received nearly $800,000 in funding to advance a novel multiple sclerosis therapy that targets excitotoxicity to halt disease progression and repair nerve damage. - The experimental compound has demonstrated the ability to restore motor skills and repair myelin in animal models, even when administered after symptoms appeared. - The therapy could mark Canada's first regenerative treatment for MS, offering hope to restore previously lost functions in patients with the neurodegenerative disease. - The research is entering final preclinical testing stages to prepare for human clinical trials, with patent protection secured and industry partnerships being sought.
- A world-first randomized controlled trial involving 76 patients found that 12 weeks of cognitive behavioral therapy or exercise programs significantly improved heart function in patients with takotsubo syndrome. - Both interventions increased the heart's energy production and patients' exercise capacity, with walking distances improving from 402 to 458 meters in the CBT group and to 528 meters in the exercise group. - The breakthrough research, presented at the European Society of Cardiology Congress, offers hope for treating a condition that affects 5,000 Britons annually and doubles the risk of early death.
- A UK study of over 60,000 patients found that GLP-1 receptor agonists significantly improved asthma control scores in obese individuals with asthma compared to matched controls. - The improvements occurred despite modest weight loss of only 0.9 kg over one year, suggesting anti-inflammatory mechanisms beyond weight reduction may contribute to respiratory benefits. - Researchers propose GLP-1 drugs could offer an alternative to steroid treatments for obese asthma patients who often show resistance to standard inhaled corticosteroids. - The findings add to growing evidence of GLP-1 drugs' therapeutic potential beyond diabetes and weight management, though further research is needed to establish direct respiratory treatment applications.
